Ex-Novo executive signs at Radius to capitalize on Amgen's bone-drug setback
admin 17th July 2017 Uncategorised 0With Amgen’s competing bone drug newly sidelined, Radius has a big opportunity ahead with its Tymlos launch, and now it has a new CEO to lead the way. Jesper Høiland, former president of Novo Nordisk’s U.S. business, has signed on to challenge Eli Lilly’s Forteo—and its forthcoming generics—in the osteoporosis market.
More: Ex-Novo executive signs at Radius to capitalize on Amgen's bone-drug setback
Source: fierce